PA
KLAC icon

PharVision Advisers’s KLA KLAC Stock Holding History

PharVision Advisers’s Portfolio KLAC Stock Details KLAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,950
Closed -$264K – 729
2025
Q2 		$264K Buy
+2,950
New +$222K 0.38% 112
2025
Q1 		– Sell
-5,840
Closed -$368K – 402
2024
Q4 		$368K Buy
+5,840
New +$395K 0.31% 95

Other funds holding KLAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

PharVision Advisers's KLAC Position: Q3 2025 in Review

PharVision Advisers sold out of KLA (KLAC) in Q3 2025, closing a stake of 2,950 shares — an estimated $264K sold.

PharVision Advisers first reported a position in KLAC in Q4 2024 and held it in 2 quarters. The position peaked at $368K in Q4 2024. 1,735 funds tracked by Wall St. Rank hold KLAC as of Q3 2025.

  • PharVision Advisers reported no remaining KLA position as of Q3 2025 after selling out during the quarter.
  • PharVision Advisers sold 2,950 KLA shares in Q3 2025, an estimated $264K.
  • PharVision Advisers first reported a position in KLA in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's KLA position peaked at $368K in Q4 2024.
  • 1,735 funds tracked by Wall St. Rank held KLA as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.